According to a market report, published by Sheer Analytics and Insights, the total human microbiome market is projected to reach USD 1992 million by 2032 from USD 200 million in 2023, at a CAGR of 29.1% from 2023 to 2032. The COVID-19 pandemic has negatively impacted healthcare sectors and made a huge disruption to clinical trial research across the globe. Later, the crisis badly has disrupted the business of several companies and including clinical studies and clinical trials of microbiome-based products. However, the government of several countries has given relaxation on a few restrictions regarding COVID-19 and the uprising of virtual clinical trials. Thus, the R&D activities have started to recover from the end of 2021 onwards. Currently, new research activities are setting up an alliance between microbiota compositions and the levels of cytokines. It is proved that COVID-19 is a respiratory illness and any person with dysbiosis in the GI tract is susceptible to COVID-19 symptoms. Additionally, such studies and research are trying to set up whether agitation in microbiome composition could permanently counter the ill effects of the SARS-CoV-2 virus and cure an individual.
The human microbiome plays an essential role in improving the effectiveness of therapeutic compounds. Several studies have proved that the correct combination of microbes in an individual’s body is very favorable for treating different conditions. Therefore, this kind of association between any specific disease and microbes can generate a new chance for medicine developers or manufacturers. As microbes are sources of enzymes, therefore, vaccine manufacturing companies can use these in several therapeutic applications, such as for new therapies. Furthermore, few studies have shown that the lung microbiome plays a vital role in generating immune responses against some viruses and it might affect against the COVID-19 as well. Therefore, these studies and research are the major drivers for the microbiome which is witnessing the growth of this human microbiome market across the globe.
Request a Sample Copy of Report: https://www.sheeranalyticsandinsights.com/request-sample/human-microbiome-market-21
The increasing geriatric population and diseases which is related to human lifestyle are the other main factors that are helping this human microbiome market to have profitable growth. In case, lowering the level of microbiota might increase the growth of fatal diseases such as ulcerative colitis C and Clostridium difficile, among others. Antimicrobial resistance or AMR has long been a major contributor to the growth of the human microbiome market across the globe. In addition, the government from various countries is increasing their funding to support the research study and it is anticipated to make a high impact by rendering drivers to increase the market growth.
Key players such as DuPont, Second Genome, Series Therapeutics, Synthetic Biologics, Yakult, ENTEROME Bioscience, Seres Therapeutics, 4D Pharma, Evelo Biosciences, OptiBiotix health, Synlogic, Kaleido, BiomX, Viome Inc, Luxia Scientific, Atlas Biomed, Bione, Metabiomics, Ferring Pharmaceuticals, FlightPath, among others are leading the market across the globe. These major players are focusing on developing new drugs and providing them to healthcare sectors to fight viruses and diseases. Further, companies are enhancing their business growth by implementing new strategies to stay ahead in the competitive market.
The Global Human Microbiome Market Has Been Segmented Into:
The Global Human Microbiome Market – by Diseases:
- Cancer
- Diabetes
- Obesity
- Autoimmune Disorders
- Mental Disorders
- Cancer
- And Other Diseases
The Global Human Microbiome Market – by Product:
- Consumables
- Instruments
The Global Human Microbiome Market – by Technology:
- Cell Culture Technology
- Omics Technology
- Computational Tools
- High-Throughput technology
The Global Human Microbiome Market – by End-User:
- Probiotics
- Prebiotics
- Foods
- Drugs and Diagnostic Services
- Medicated Foods
The Global Human Microbiome Market – by Region:
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe Countries
Asia-Pacific
- India
- China
- Japan
- South Korea
- North Korea
- Rest of Asian Countries
LAMEA
- Brazil
- Saudi Arabia
- Rest of LAMEA
Click full report at https://www.sheeranalyticsandinsights.com/market-report-research/humanoid-robots-market-21
About Us
Sheer Analytics and Insights Private Limited is market research, consulting, and IT services company. We as a company believe in providing point to point data and its analysis with the combination of our human and automation integration. Sheer Analytics and Insights cover majorly eight industry verticals, including chemicals, life science, communications, and electronics, materials, consumer goods, defense, and BFSI sector.
Sheer Analytics believes in quality work and ensures that the product delivered to the client is meaningful for them. We publish reports based on our advanced analytics reports, which are generated with the help of our in-house databases, external databases, and artificial intelligence integration processes. We stand out from other market research companies in terms of integrating facts with meaningful insights for forecasting.
Contact:
Abhigyan Sengupta
Sheer Analytics and Insights
Email: query@sheeranalyticsandinsights.com
+1-414-240-5010
No comments:
Post a Comment